Squarepoint’s Nabriva Therapeutics NBRV Stock Holding History
Bought
Maintained
Sold
Other funds holding NBRV
SM
AICPI
Squarepoint's NBRV Position: Q2 2021 in Review
Squarepoint sold out of Nabriva Therapeutics (NBRV) in Q2 2021, closing a stake of 6,265 shares — an estimated $260K sold.
Squarepoint first reported a position in NBRV in Q4 2017 and held it in 3 quarters. The position peaked at $260K in Q1 2021. 31 funds tracked by Wall St. Rank hold NBRV as of Q2 2021.
- Squarepoint reported no remaining Nabriva Therapeutics position as of Q2 2021 after selling out during the quarter.
- Squarepoint sold 6,265 Nabriva Therapeutics shares in Q2 2021, an estimated $260K.
- Squarepoint first reported a position in Nabriva Therapeutics in Q4 2017 and held it in 3 quarters.
- Squarepoint's Nabriva Therapeutics position peaked at $260K in Q1 2021.
- 31 funds tracked by Wall St. Rank held Nabriva Therapeutics as of Q2 2021.
Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.